These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17565644)

  • 1. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury.
    Tu CT; Guo JS; Wang M; Wang JY
    J Gastroenterol Hepatol; 2007 Jun; 22(6):877-84. PubMed ID: 17565644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
    Rodríguez-Vilarrupla A; Laviña B; García-Calderó H; Russo L; Rosado E; Roglans N; Bosch J; García-Pagán JC
    J Hepatol; 2012 May; 56(5):1033-1039. PubMed ID: 22245887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
    Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of celecoxib on experimental liver fibrosis in rat.
    Hui AY; Leung WK; Chan HL; Chan FK; Go MY; Chan KK; Tang BD; Chu ES; Sung JJ
    Liver Int; 2006 Feb; 26(1):125-36. PubMed ID: 16420518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Morphology of portal hypertension at the early stage of liver damage induced by CCl4: an experimental study with dogs].
    Zhang RP; Zhang WH; Xue DB; Wei YW
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(13):1118-21. PubMed ID: 15312518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats.
    Gandhi CR; Nemoto EM; Watkins SC; Subbotin VM
    Liver; 1998 Feb; 18(1):39-48. PubMed ID: 9548266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
    Zhang CH; Zheng L; Gui L; Lin JY; Zhu YM; Deng WS; Luo M
    Clin Res Hepatol Gastroenterol; 2018 Apr; 42(2):118-125. PubMed ID: 29031875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis.
    Yao Q; Lin Y; Li X; Shen X; Wang J; Tu C
    Toxicol Lett; 2013 Sep; 222(1):72-82. PubMed ID: 23845850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of platelet activating factor and its antagonist on portal hypertension associated with liver cirrhosis: an experiment with rats].
    Wang CP; Han J; Ma XM; Dong K; Xiang Y; Su SH; Feng YY; Yang YP
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3337-41. PubMed ID: 16409839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure.
    Huang HC; Haq O; Utsumi T; Sethasine S; Abraldes JG; Groszmann RJ; Iwakiri Y
    J Cell Mol Med; 2012 May; 16(5):1125-33. PubMed ID: 21801303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats.
    Kose F; Besen A; Paydas S; Balal M; Gonlusen G; Inal T; Dogan A; Kibar M
    Clin Exp Nephrol; 2010 Feb; 14(1):22-7. PubMed ID: 19789943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.
    Yang Y; Nemoto EM; Harvey SA; Subbotin VM; Gandhi CR
    Gut; 2004 Jun; 53(6):877-83. PubMed ID: 15138217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury.
    Liang B; Guo XL; Jin J; Ma YC; Feng ZQ
    World J Gastroenterol; 2015 May; 21(17):5271-80. PubMed ID: 25954100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thromboxane A2 in early BDL-induced portal hypertension.
    Yokoyama Y; Xu H; Kresge N; Keller S; Sarmadi AH; Baveja R; Clemens MG; Zhang JX
    Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G453-60. PubMed ID: 12431905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver.
    Chen YW; Liu BW; Zhang YJ; Chen YW; Dong GF; Ding XD; Xu LM; Pat B; Fan JG; Li DG
    J Hepatol; 2010 Sep; 53(3):528-36. PubMed ID: 20646773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic effects of protocatechuic aldehyde on experimental liver fibrosis.
    Li C; Jiang W; Zhu H; Hou J
    Pharm Biol; 2012 Apr; 50(4):413-9. PubMed ID: 22129045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.